TCGX
News,Asia,Biotech / MedTech,China,Investments,Venture Capital
TCGX closes $600M fund to invest in Asian biotech
TCGX has closed an oversubscribed $600 million fund to invest across stages in Asia-based biotechnology companies and is opening Hong Kong and Shanghai offices.
October 12, 2026
Fujitsu and Paradigm test AI screening for Japan trials
November 20, 2026
MetaComp adds about $10M from Tether and Further
November 20, 2026
Fujitsu and Paradigm test AI screening for Japan trials
November 20, 2026
MetaComp adds about $10M from Tether and Further
November 20, 2026




